Loading financial data...

ARROWHEAD PHARMACEUTICALS, INC. (ARWR) Financial Statements | Global Financial Data

ARROWHEAD PHARMACEUTICALS, INC.

ARWRSEC EDGAR

Pharmaceutical Preparations(DE)CIK: 879407

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue from Contract with Customer, Excluding Assessed Tax	$240.7M	$243.2M	$138.3M	$88.0M	$168.8M
Research and Development Expense	$353.2M	—	—	—	—
Operating Expenses	$445.7M	$421.7M	$287.3M	$181.2M	$107.6M
Operating Income (Loss)	-$205.0M	-$178.5M	-$149.0M	-$93.2M	$61.2M
Interest Expense	—	—	$0.00	—	—
Nonoperating Income (Expense)	-$1.5M	$5.8M	$8.2M	$8.6M	$7.0M
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$206.5M	-$172.7M	-$140.8M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$1.1B	$765.6M	$691.9M	$710.1M	$522.5M
Assets, Current	$695.5M	$416.5M	$405.3M	$384.6M	$322.4M
Cash and Cash Equivalents, at Carrying Value	—	—	—	—	$143.6M
Accounts Receivable, after Allowance for Credit Loss, Current	$0.00	—	$1.4M	$10.3M	$846.0K
Liabilities, Current	$103.2M	$105.5M	$138.8M	$146.5M	$40.7M
Accounts Payable, Current	$11.4M	$35.9M	$2.9M	$9.5M	$6.8M
Stockholders' Equity Attributable to Parent	$185.4M	$271.3M	$398.5M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$153.9M	-$136.1M	$171.3M	-$95.8M	$173.0M
Net Cash Provided by (Used in) Investing Activities	-$96.2M	-$5.4M	-$141.7M	-$240.8M	-$47.7M
Net Cash Provided by (Used in) Financing Activities	$253.1M	$65.2M	$11.3M	$257.9M	$66.4M
Payments to Acquire Property, Plant, and Equipment	$176.7M	$52.8M	$23.6M	$12.0M	$12.0M

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)